Chiasma (NASDAQ:CHMA) Trading Up 7.7%

Chiasma Inc (NASDAQ:CHMA)’s stock price was up 7.7% during trading on Tuesday . The company traded as high as $5.50 and last traded at $5.47, approximately 408,500 shares were traded during mid-day trading. An increase of 0% from the average daily volume of 406,719 shares. The stock had previously closed at $5.08.

A number of equities research analysts have commented on CHMA shares. Brookline Capital Management restated a “buy” rating on shares of Chiasma in a report on Wednesday, July 24th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Chiasma in a report on Tuesday, July 23rd. Cantor Fitzgerald set a $18.00 price objective on shares of Chiasma and gave the company a “buy” rating in a report on Friday, June 28th. ValuEngine cut shares of Chiasma from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research cut shares of Chiasma from a “buy” rating to a “hold” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Chiasma currently has an average rating of “Buy” and a consensus target price of $12.30.

The stock has a market capitalization of $212.28 million, a price-to-earnings ratio of -4.28 and a beta of 1.18. The business’s fifty day moving average price is $5.93 and its 200-day moving average price is $5.91.

Chiasma (NASDAQ:CHMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. On average, sell-side analysts anticipate that Chiasma Inc will post -1.09 EPS for the current year.

In other news, Director Roni Mamluk sold 10,000 shares of Chiasma stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $6.35, for a total transaction of $63,500.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $63,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott Minick acquired 9,818 shares of Chiasma stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average price of $5.19 per share, with a total value of $50,955.42. Following the completion of the acquisition, the director now directly owns 62,531 shares of the company’s stock, valued at $324,535.89. The disclosure for this purchase can be found here. 8.30% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC boosted its holdings in Chiasma by 35.4% during the second quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,722 shares during the last quarter. Millennium Management LLC purchased a new position in Chiasma during the fourth quarter worth about $41,000. Quantitative Systematic Strategies LLC purchased a new position in Chiasma during the second quarter worth about $100,000. Dimensional Fund Advisors LP boosted its holdings in Chiasma by 20.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 16,658 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in Chiasma by 27.8% during the fourth quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 16,996 shares during the last quarter. Institutional investors and hedge funds own 73.17% of the company’s stock.

Chiasma Company Profile (NASDAQ:CHMA)

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Recommended Story: How does a reverse stock split work?

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.